Page 92 - GTM-3-3

Global Translational Medicine

CASE REPORT
Pancreatoduodenectomy for pancreatic

adenocarcinoma in a patient with systemic
lupus erythematosus who underwent renal

transplantation: A case report

Ran Wei , Dailei Qin , Zehui Yao , Xiaojun Lin* , and Bokang Cui*
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center
for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guandong, China

Abstract

The incidence of pancreatic cancer is elevated in patients with systemic lupus
erythematosus (SLE), particularly those who have undergone renal transplantation.
However, the feasibility of performing a pancreaticoduodenectomy (PD) for this
specific patient group remains uncertain. Here, we present a case of a 44-year-old
male with SLE and a history of renal transplantation who was newly diagnosed with
pancreatic cancer. The patient successfully underwent PD combined with resection
and reconstruction of the superior mesenteric vein and had an uneventful post-
operative course. In silico analysis revealed higher ratios of naïve B cells, CD8 T cells,
+
*Corresponding authors: CD4 memory-activated T cells, and monocytes in the tumor tissue of this patient
+
Bokang Cui
(cuibk@sysucc.org.cn) compared to most patients in The Cancer Genome Atlas and PACA-AU datasets
Xiaojun Lin (exceeding the mean + standard error value for each cell type). In addition, the
(linxj@sysucc.org.cn) patient exhibited higher proportions of naïve B cells, memory B cells, CD4 memory-
+
Citation: Wei R, Qin D, Yao Z, Lin activated T cells, regulatory T cells, resting natural killer cells, and activated dendritic
X, Cui B. Pancreatoduodenectomy cells in the lymph nodes compared to patients in the GSE103787 dataset (exceeding
for pancreatic adenocarcinoma the mean + standard error value for each cell type). Furthermore, expression levels
in a patient with systemic lupus
erythematosus who underwent of cytotoxic marker genes (granzyme B and perforin 1) were higher in both the
renal transplantation: A case report. tumor tissue and lymph nodes compared to public datasets (exceeding the mean +
Global Transl Med. 2024:3(3):2893. standard error value). In conclusion, this case demonstrates that a patient with SLE
doi: 10.36922/gtm.2893
and renal transplantation can tolerate PD. In addition, it provides the first description
Received: February 5, 2024 of this patient group’s unique anti-tumor immune microenvironment through
Accepted: May 22, 2024 in silico analysis.
Published Online: September 4,
2024 Keywords: Case report; Pancreatic cancer; Systemic lupus erythematosus; Renal
Copyright: © 2024 Author(s). transplantation; Immune microenvironment
This is an Open-Access article
distributed under the terms of the
Creative Commons Attribution
License, permitting distribution,
and reproduction in any medium, 1. Introduction
provided the original work is
properly cited. Globally, the prevalence of systemic lupus erythematosus (SLE) is estimated to be
Publisher’s Note: AccScience between 30 and 150/100,000, with an annual incidence ranging from 2.2 to 23.1/100,000
Publishing remains neutral with individuals. It is reported that there are approximately 500,000 SLE patients in Europe
1
regard to jurisdictional claims in
published maps and institutional and 250,000 in the United States of America. Increasing evidence has revealed that SLE
affiliations. is associated with a higher incidence of cancer, particularly non-Hodgkin’s lymphomas,

Volume 3 Issue 3 (2024) 1 doi: 10.36922/gtm.2893